Dr Mike Boggild
Dr Mike Boggild has over 20 years experience in neurology, initially as a consultant neurologist at The Walton Centre in Liverpool, UK before becoming Director of Neurology at The Townsville Hospital in 2012. He has a specialist interest in Multiple Sclerosis (MS) and was the visiting neurologist to The Isle of Man for 15 years with experience across the range of neurological disorders.
After completing his neurology training in Leicester, Stoke-on-Trent and Newcastle-upon-Tyne he undertook a sabbatical at MS centres in the United States before setting up the MS service in Liverpool in 1996. The Walton multi-disciplinary MS service was later recognised by the MS society as the best comprehensive service in UK. He initiated a number of investigator led clinical studies in addition to participating in numerous multi-centre trials. In 2002 he was appointed as clinical lead and subsequently chief investigator for the 5,000 patient UK MS risk-sharing scheme; a prospective 10 year study of the long-term outcomes and cost-effectiveness of disease modifying therapies, a role he relinquished in 2012 on moving to Australia.
He maintains a number of active research collaborations, most recently with academics at JCU and contributed to 2014 Australia/New Zealand guidelines on MS management. He has authored over 50 peer reviewed publications and speaks regularly at national and international meetings and symposia. He is a member of the Scientific Advisory Committee to the Australia and New Zealand Association of Neurologists (ANZAN).
Specialist Qualifications
- MB ChB Bachelor of Medicine and Bachelor of Surgery (University of Leicester) 1986
- MRCP (London) (Royal College of Physicians, UK) 1989
- MD (Leicester) 1994
- FRACP 2013
Memberships
- Royal College of Physicians (UK)
- Association of British Neurologists (ABN)
- Australia and New Zealand Association of Neurologists (ANZAN)
- Royal Australian College of Physicians
Recent Publications
- Time- and Region-Specific Season of Birth Effects in Multiple Sclerosis in the United Kingdom. - JAMA Neurol. 2016
- Status of diagnostic approaches to AQP4-IgG seronegative NMO and NMO/MS overlap- J Neurol. 2016
- A new era in the treatment of multiple sclerosis. - Med J Aust. 2015
- The epidemiology of multiple sclerosis in the Isle of Man: 2006-2011 - Acta Neurol Scand. 2015
- Effectiveness and cost-effectiveness of interferon beta and glatiramer acetate in the UK Multiple Sclerosis Risk Sharing Scheme at 6 years: a clinical cohort study with natural history comparator. - Lancet Neurol. 2015
- Therapy-related acute leukaemia with mitoxantrone: four years on, what is the risk and can it be limited? - Mult Scler,.2015
- Therapeutic approaches to disease modifying therapy for multiple sclerosis in adults: an Australian and New Zealand perspective: Part 1 historical and established therapies. J Clin Neurosci. 2014
- Therapeutic approaches to disease modifying therapy for multiple sclerosis in adults: an Australian and New Zealand perspective: Part 2 new and emerging therapies and their efficacy. MS Neurology Group of the Australian and New Zealand Association of Neurologists. - J Clin Neurosci. 2014
- Therapeutic approaches to disease modifying therapy for multiple sclerosis in adults: an Australian and New Zealand perspective: Part 3 treatment practicalities and recommendations. MS Neurology Group of the Australian and New Zealand Association of Neurologists - J Clin Neurosci. 2014
- UK multiple sclerosis risk-sharing scheme: a new natural history dataset and an improved Markov model. - BMJ Open. 2014
- Role of intravenous immunoglobulin in the treatment of acute relapses of neuromyelitis optica: experience in 10 patients. - Mult Scler. 2014
- The epidemiology of neuromyelitis optica amongst adults in the Merseyside county of United Kingdom. - J Neurol. 2013
- Neuropathic pruritus (itch) in neuromyelitis optica. - Mult Scler. 2013
- The effects of long-term exposure to disease-modifying drugs during pregnancy in multiple sclerosis. - Clin Neurol Neurosurg. 2013
- Does natalizumab therapy worsen neuromyelitis optica? - Neurology. 2012
- Prognostic factors and disease course in aquaporin-4 antibody-positive patients with neuromyelitis optica spectrum disorder from the United Kingdom and Japan. - Nature. 2011
- Fasciculations and cramps: how benign? Report of four cases progressing to ALS. - J Neurol. 2011
- Immunosuppression followed by immunomodulation. - J Neurol Sci. 2009